Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Analytical Biochemistry
|
November 28, 2006
A high-throughput method for fitting dose-response curves using Microsoft Excel
Jonathan D Parsons
Antimicrobial Agents and Chemotherapy
|
April 24, 2004
Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase
Steven Bellon, Jonathan D Parsons, Yunyi Wei, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2006
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class
Nagraj Mani, Christian H Gross, Jonathan D Parsons, et al.
Antimicrobial Agents and Chemotherapy
|
February 27, 2003
Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance
Christian H Gross, Jonathan D Parsons, Trudy H Grossman, et al.
Antimicrobial Agents and Chemotherapy
|
November 23, 2006
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds
Trudy H Grossman, Douglas J Bartels, Steve Mullin, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2010
Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase
Steven M Ronkin, Michael Badia, Steve Bellon, et al.
Journal of Medicinal Chemistry
|
August 12, 2008
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships
Paul S Charifson, Anne-Laure Grillot, Trudy H Grossman, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Analytical Biochemistry
|
November 28, 2006
A high-throughput method for fitting dose-response curves using Microsoft Excel
Jonathan D Parsons
Antimicrobial Agents and Chemotherapy
|
April 24, 2004
Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase
Steven Bellon, Jonathan D Parsons, Yunyi Wei, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2006
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class
Nagraj Mani, Christian H Gross, Jonathan D Parsons, et al.
Antimicrobial Agents and Chemotherapy
|
February 27, 2003
Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance
Christian H Gross, Jonathan D Parsons, Trudy H Grossman, et al.
Antimicrobial Agents and Chemotherapy
|
November 23, 2006
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds
Trudy H Grossman, Douglas J Bartels, Steve Mullin, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2010
Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase
Steven M Ronkin, Michael Badia, Steve Bellon, et al.
Journal of Medicinal Chemistry
|
August 12, 2008
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships
Paul S Charifson, Anne-Laure Grillot, Trudy H Grossman, et al.
Page
of 1